Kane Biotech Inc (KNE.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 126 | 1,283 | 620 | 52 | -1,904 |
| Cost of Goods | 213 | 724 | 260 | 12 | -1,022 |
| Gross Profit | -87 | 559 | 360 | 40 | -881 |
| Operating Expenses | 933 | 1,170 | 1,463 | 1,228 | -273 |
| Operating Income | -1,021 | -611 | -1,103 | -1,188 | -608 |
| Interest Expense | 62 | 65 | 101 | 318 | 266 |
| Other Income | 0 | -3 | -12 | 12 | -30 |
| Pre-tax Income | -1,083 | -679 | -1,216 | -1,494 | -904 |
| Net Income Continuous | 227 | -679 | -1,216 | -1,494 | -904 |
| Net Income Discontinuous | -1,310 | 73 | 10,418 | 147 | N/A |
| Minority Interests | 0 | 0 | -19 | -49 | 30 |
| Net Income | $-1,083 | $-606 | $9,183 | $-1,396 | $-1,582 |
| EPS Basic Total Ops | -0.07 | 0.00 | 0.07 | -0.01 | -0.01 |
| EPS Basic Continuous Ops | -0.10 | -0.01 | -0.01 | -0.01 | 0.00 |
| EPS Basic Discontinuous Ops | 0.10 | -0.01 | 0.08 | 0.00 | N/A |
| EPS Diluted Total Ops | -0.07 | 0.00 | 0.06 | -0.01 | -0.01 |
| EPS Diluted Continuous Ops | -0.10 | -0.01 | -0.01 | -0.01 | 0.00 |
| EPS Diluted Discontinuous Ops | 0.09 | -0.01 | 0.07 | 0.00 | N/A |
| EBITDA(a) | $-957 | $-567 | $-1,061 | $-1,122 | $-590 |